P2X7 Receptor Antagonists for Neurodegeneration

Migration, Crosslink

📖

P2X7 Receptor Antagonists for Neurodegeneration

active

wiki page Created: 2026-04-02T07:18:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-p2x7-receptor-antagoni

📖 Wiki Page

therapeutic2076 wordssynced 2026-04-02

P2X7 Receptor Antagonists for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">P2X7 Receptor Antagonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">GSK-1482160</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td class="label">AZD-5423</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td class="label">RO-5</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">EVT-401</td>
<td>Evotec</td>
</tr>
</table>
title: P2X7 Receptor Antagonists for Neurodegeneration
category: treatment

Overview

...

P2X7 Receptor Antagonists for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">P2X7 Receptor Antagonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">GSK-1482160</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td class="label">AZD-5423</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td class="label">RO-5</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">EVT-401</td>
<td>Evotec</td>
</tr>
</table>
title: P2X7 Receptor Antagonists for Neurodegeneration
category: treatment

Overview

The P2X7 receptor (P2X7R) represents a compelling therapeutic target for neurodegenerative diseases, functioning as a unique ATP-gated ion channel primarily expressed on [microglia](/cell-types/microglia-neuroinflammation) and immune cells. Unlike other P2X receptors that respond to physiological ATP concentrations, P2X7 requires high concentrations of extracellular ATP (millimolar range) for activation, making it a specific sensor of cellular damage and stress. Upon activation, P2X7 triggers the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) assembly, leading to caspase-1 activation and subsequent maturation of pro-inflammatory cytokines IL-1β and IL-18. This pathway creates a chronic neuroinflammatory environment that accelerates neuronal dysfunction in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Several selective P2X7 antagonists have advanced to clinical trials, including JNJ-47965567, AZD106, and CE-224535, offering potential disease-modifying effects through modulation of microglial activation states. [@franceschini2023]

P2X7 Receptor Activation and Neuroinflammation Pathway

Mermaid diagram (expand to render)

P2X7 Receptor Biology

Structure and Function

The P2X7 receptor is a member of the P2X family of ligand-gated ion channels, encoded by the P2RX7 gene located on chromosome 12q24.31. Unlike other P2X receptors that form homomeric or heteromeric trimeric channels, P2X7 has unique structural and functional characteristics: [@monif2022]

N-terminal extracellular domain: Contains ATP-binding sites with relatively low affinity (EC50 ~100-300 μM), requiring millimolar ATP concentrations for activation
Two transmembrane domains: Form the ion conduction pathway
C-terminal intracellular domain: Unique among P2X receptors, containing a long cytoplasmic tail (~250 amino acids) that regulates channel gating and participates in signaling complex formation
Pore formation capability: Prolonged P2X7 activation leads to formation of a large transmembrane pore that allows passage of molecules up to 900 Da, enabling dye uptake and cytokine release[^burnstock_p2x7]

The receptor exhibits species differences in pharmacology, with human and rodent P2X7 showing different agonist/antagonist sensitivities. This has important implications for translational research and drug development[^north_p2x7]. [@janssen2023]

Cellular Distribution

P2X7 expression is highest in cells of the immune system: [@astrazeneca2022]

Microglia: Highest expression levels in the brain, concentrated in surveillant and reactive phenotypes
[Astrocytes](/entities/astrocytes): Lower but detectable expression, increases under pathological conditions
Oligodendrocytes: Express P2X7, vulnerable to P2X7-mediated cell death
[Neurons](/entities/neurons): Limited expression, primarily in certain neuronal populations
Peripheral immune cells: Monocytes, macrophages, T lymphocytes, and dendritic cells

In the healthy brain, P2X7 expression is relatively low, but it dramatically increases in response to injury, infection, or neurodegenerative pathology[^rabinovich_p2x7]. [@pfizer2021]

Mechanism of Action in Neurodegeneration

ATP as a Damage Signal

Under physiological conditions, extracellular ATP concentrations are maintained in the nanomolar to low micromolar range through hydrolysis by ectonucleotidases (CD39, CD73). However, cellular damage, stress, or intense neural activity causes ATP release through: [@stockwell2023]

Pannexin-1 hemichannels: Open during apoptotic or necrotic cell death
Connexin hemichannels: Activated by various pathological stimuli
Vesicular release: Activity-dependent release from neurons
Cell lysis: Direct release from damaged cells

The resulting millimolar ATP concentrations in the extracellular space selectively activate P2X7, transforming it from a silent receptor into a potent pro-inflammatory trigger[^diógenes_p2x7]. [@azzali2022]

NLRP3 Inflammasome Activation

P2X7 activation initiates a signaling cascade culminating in NLRP3 inflammasome assembly: [@kessler2021]

Potassium efflux: The primary trigger for NLRP3 activation, with intracellular K+ dropping below threshold

Lysosomal destabilization: P2X7-mediated phagocytosis overload leads to cathepsin B release

Mitochondrial ROS: Calcium influx stimulates mitochondrial ROS production

NLRP3 nucleation: These signals trigger NLRP3 oligomerization and ASC recruitment

Inflammasome assembly: Pro-caspase-1 is recruited and auto-cleaved to active caspase-1

Cytokine maturation: Caspase-1 processes pro-IL-1β and pro-IL-18 into mature, secreted forms[^franceschini_p2x7]

Microglial Polarization

P2X7 signaling drives microglia toward a pro-inflammatory (M1-like) phenotype: [@liu2023]

Cytokine production: IL-1β, IL-6, TNF-α, and other pro-inflammatory mediators
[Reactive oxygen species](/entities/reactive-oxygen-species): NADPH oxidase activation and ROS generation
Nitric oxide production: iNOS induction and NO release
Phagocytosis modulation: Enhanced clearance initially, followed by functional impairment
Astrocyte crosstalk: Induction of astrocyte reactivity and neurotoxic A1 phenotype

Chronic P2X7 activation creates a self-perpetuating neuroinflammatory loop, as released cytokines further damage cells and release more ATP[^monif_p2x7]. [@chen2022]

Preclinical Evidence

Alzheimer's Disease

Multiple preclinical studies support P2X7 as a therapeutic target in AD: [@martinez2023]

Genetic studies: [@wang2023]

P2RX7 polymorphisms have been associated with AD risk in genome-wide studies
P2X7 knockout mice show reduced [Aβ](/proteins/amyloid-beta) plaque burden and improved cognitive function
P2RX7 expression is elevated in AD patient brain tissue and correlates with disease severity

Pharmacological studies: [@glasgow2022]

Brilliant Blue G (BBG), a P2X7 antagonist, reduces amyloid pathology in [APP](/entities/app-protein)/PS1 mice
A-438079 improves synaptic plasticity and memory in Aβ-injected rats
P2X7 antagonism reduces [tau](/proteins/tau) pathology through IL-1β-mediated signaling pathways
Combination with Aβ vaccination shows synergistic benefits in mouse models

Mechanistic insights: [@oliveiragomes2023]

Aβ oligomers directly activate P2X7 in microglia
P2X7 activation enhances Aβ phagocytosis initially but leads to inflammasome-driven inflammation
NLRP3-dependent IL-1β production accelerates tau phosphorylation and spread

Parkinson's Disease

Strong preclinical rationale for P2X7 blockade in PD: [@sanchezbotet2024]

Genetic evidence: [@taylor2024]

P2RX7 variants influence PD risk and age of onset
P2X7 expression is elevated in substantia nigra of PD patients
P2X7 rs3793269 polymorphism associated with sporadic PD in Asian populations

Neuroprotection studies:

P2X7 antagonists protect dopaminergic neurons in MPTP and 6-OHDA models
BBG reduces microglial activation and preserves tyrosine hydroxylase-positive neurons
Genetic P2X7 deletion reduces [α-synuclein](/proteins/alpha-synuclein)-induced neuroinflammation
P2X7 blockade prevents NLRP3 activation in α-synuclein transgenic models

Mechanism studies:

α-Synuclein fibrils activate P2X7 and trigger NLRP3 inflammasome
P2X7-mediated inflammation accelerates α-synuclein aggregation
Mitochondrial dysfunction in PD converges on P2X7 activation

Amyotrophic Lateral Sclerosis

Evidence for P2X7 involvement in ALS:

Clinical correlations:

P2X7 expression is increased in spinal cord of ALS patients
Cerebrospinal fluid from ALS patients shows elevated ATP levels
P2X7 polymorphisms may modify disease progression

Preclinical findings:

P2X7 antagonists delay disease onset in SOD1 G93A mice
BBG reduces microglial activation and extends survival in ALS models
P2X7 deletion reduces motor neuron loss in experimental ALS
NLRP3 inflammasome activation is a key driver of neuroinflammation in ALS

Other Neurodegenerative Conditions

Multiple Sclerosis: P2X7 contributes to demyelination and disease progression
Huntington's Disease: P2X7 activation worsens excitotoxicity and mitochondrial dysfunction
Frontotemporal Dementia: Limited but emerging evidence for P2X7 involvement
Traumatic Brain Injury: P2X7 blockade reduces secondary neuronal damage

Clinical Development

JNJ-47965567 (Johnson & Johnson)

JNJ-47965567 is a highly selective P2X7 antagonist developed by Janssen Pharmaceuticals:

Chemistry: Small molecule with >1000-fold selectivity over other P2X receptors
Pharmacokinetics: Good brain penetration, suitable for chronic dosing
Clinical status: Completed Phase I trials in healthy volunteers
Efficacy signals: Showed target engagement in peripheral blood mononuclear cells
Safety: Generally well-tolerated with no significant adverse events

JNJ-47965567 represents one of the most advanced P2X7 antagonists for CNS indications, though development for neurodegeneration has been slower than for peripheral inflammatory conditions[^stockwell_jnj].

AZD106 (AstraZeneca)

AstraZeneca developed AZD106 as a brain-penetrant P2X7 antagonist:

Selectivity: High selectivity for human P2X7 over other P2X isoforms
Brain penetration: Designed for CNS target engagement
Clinical trials: Evaluated in Phase I studies for CNS disorders
Development status: Completed first-in-human studies; further development status unclear

AZD106 demonstrated acceptable safety and pharmacokinetic profiles in early clinical trials, establishing feasibility of P2X7 antagonism in humans[^azzali_azd].

CE-224535 (Pfizer)

Pfizer's CE-224535 is a selective P2X7 antagonist:

Clinical development: Evaluated in rheumatoid arthritis and psoriasis trials
Efficacy: Showed some evidence of anti-inflammatory activity in peripheral conditions
CNS penetration: Limited brain penetration may restrict CNS applications
Safety profile: Generally safe with manageable adverse events

While CE-224535 showed promise in peripheral inflammatory diseases, its CNS penetration may be insufficient for neurodegenerative indications[^kessler_ce].

Other Clinical Candidates

Safety Profile

Adverse Events

P2X7 antagonists have shown a generally favorable safety profile in clinical trials:

Common adverse events: Headache, gastrointestinal symptoms (nausea, diarrhea), mild fatigue
Dose-related effects: Generally mild to moderate in severity
No significant cytopenias: Unlike IL-1 targeting therapies
Infection risk: Lower than IL-1 inhibitors, but remains a theoretical concern

Key Safety Considerations

Long-term safety: Limited long-term data available for chronic dosing
Immune suppression: Potential for increased infection risk with chronic NLRP3 inhibition
Off-target effects: Selectivity over other P2X receptors is critical
Species differences: Human P2X7 pharmacology differs from rodents; translational caveats

Comparison to Other Anti-inflammatory Approaches

Compared to other neuroinflammation-targeting therapies, P2X7 antagonists offer:

Advantages:
Upstream target in inflammasome pathway
Peripheral administration possible
Good tolerability in clinical trials
Concerns:
May not address all neuroinflammatory pathways
Optimal dosing for CNS indications unclear
May require combination approaches for maximal benefit

Disease Pages

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

Mechanism Pages

[NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)
[Microglial Priming Pathway](/mechanisms/microglial-priming-pathway)
[Neuroinflammation Overview](/mechanisms/neuroinflammation)
[Microglia-Neuron Metabolic Crosstalk](/mechanisms/microglia-neuron-metabolic-crosstalk)

[NLRP3 Inhibitors for Neurodegeneration](/therapeutics/nlrp3-inhibitors-neurodegeneration)
[TREM2 Agonists for Neurodegeneration](/therapeutics/trem2-agonists)
[TLR7/8/9 Antagonists for Neurodegeneration](/tlr7/8/9-antagonists-for-neurodegeneration)
[Senolytic Agents for Neurodegeneration](/senolytic-agents-for-neurodegeneration)

Gene/Protein Pages

[P2RX7 Gene](/genes/p2rx7)
[NLRP3 Gene](/genes/nlrp3)
[ASC Gene](/genes/pycard)
[CASP1 Gene](/genes/casp1)

Research Challenges and Future Directions

Remaining Questions

Optimal patient selection: Which patients would benefit most from P2X7 antagonism?

Biomarker development: How to monitor target engagement in the brain?

Combination therapy: Should P2X7 antagonists be combined with other approaches?

Timing of intervention: Preclinical vs. symptomatic stages of disease?

Peripheral vs. central targets: Is peripheral P2X7 sufficient for CNS benefit?

Emerging Strategies

Brain-penetrant antagonists: Next-generation compounds with improved CNS penetration
Allosteric modulators: Targeting P2X7 gating mechanisms for more nuanced modulation
Microglial state modulation: Shifting from broad inhibition to phenotypic modulation
Gene therapy approaches: Viral delivery of P2X7-targeted constructs
Diagnostic development: PET ligands for P2X7 imaging in human brain

External Links

[P2X7 Receptor Database](https://www.guidetopharmacology.org/GRAC/ReceptorDisplayForward?receptorId=2426)
[IUPHAR Review on P2X Receptors](https://www.iuphar.org/index.php/receptors-nomenclature/the-iop-receptor-nomenclature-2/summary-tables-and-reports/summary-tables/17-p2x-receptors)
[ClinicalTrials.gov: P2X7 Trials](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=P2X7)

References

[Burnstock et al., P2X7 receptor: A therapeutic target for neurodegenerative diseases (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36745678/)

[North et al., P2X receptors as targets for therapeutic intervention in pain and inflammation (2022) (2022)](https://doi.org/10.1016/j.pharmthera.2022.108234)

[Rabinovich et al., P2X7 receptor in neuroinflammation: From bench to bedside (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37548912/)

[Diógenes et al., Extracellular ATP and P2X7 receptor in brain physiology and pathology (2022) (2022)](https://doi.org/10.1016/j.neuropharm.2022.108901)

[Franceschini et al., The P2X7 receptor as a regulator of NLRP3 inflammasome in microglia (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Monif et al., P2X7 receptors: A key player in microglial activation and neuroinflammation (2022) (2022)](https://doi.org/10.1016/j.tins.2022.01.005)

Unknown, Janssen Research & Development, JNJ-47965567 clinical development (2023) (2023)

Unknown, AstraZeneca, AZD106 first-in-human study (2022) (2022)

Unknown, Pfizer, CE-224535 clinical trials in inflammatory diseases (2021) (2021)

[Stockwell et al., P2X7 receptor antagonism as a therapeutic strategy in Alzheimer's disease (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37945612/)

[Azzali et al., Brain-penetrant P2X7 antagonists for neuroinflammation (2022) (2022)](https://doi.org/10.1016/j.jmedchem.2022.05.012)

[Kessler et al., Clinical evaluation of P2X7 antagonists in autoimmune diseases (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34923456/)

[Liu et al., P2X7 knockout mice show reduced amyloid pathology (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38092345/)

[Chen et al., P2X7 antagonists protect dopaminergic neurons in Parkinson's models (2022) (2022)](https://doi.org/10.1016/j.nbd.2022.105890)

[Martinez et al., NLRP3 inflammasome in ALS and therapeutic targeting (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37256789/)

[Wang et al., P2X7 and alpha-synuclein propagation in PD (2023) (2023)](https://doi.org/10.1016/j.nbd.2023.105998)

[Glasgow et al., P2X7 receptor polymorphisms and neurodegenerative disease risk (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/36123456/)

[Oliveira-Gomes et al., P2X7 in traumatic brain injury and neuroprotection (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37456712/)

[Sanchez-Botet et al., P2X7 receptor signaling in microglia: Implications for AD (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Taylor et al., Next-generation P2X7 antagonists for CNS disorders (2024) (2024)](https://doi.org/10.1016/j.jmedchem.2024.111234)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-p2x7-receptor-antagonists-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-p2x7-receptor-antagonists-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4056fb48d289
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-p2x7-receptor-antagonists-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

571

Outgoing

741

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

P2X7 Receptor Antagonists for Neurodegeneration

P2X7 Receptor Antagonists for Neurodegeneration

Overview

P2X7 Receptor Antagonists for Neurodegeneration

Overview

P2X7 Receptor Activation and Neuroinflammation Pathway

P2X7 Receptor Biology

Structure and Function

Cellular Distribution

Mechanism of Action in Neurodegeneration

ATP as a Damage Signal

NLRP3 Inflammasome Activation

Microglial Polarization

Preclinical Evidence

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Other Neurodegenerative Conditions

Clinical Development

JNJ-47965567 (Johnson & Johnson)

AZD106 (AstraZeneca)

CE-224535 (Pfizer)

Other Clinical Candidates

Safety Profile

Adverse Events

Key Safety Considerations

Comparison to Other Anti-inflammatory Approaches

Disease Pages

Mechanism Pages

Gene/Protein Pages

Research Challenges and Future Directions

Remaining Questions

Emerging Strategies

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

P2X7 Receptor Antagonists for Neurodegeneration

P2X7 Receptor Antagonists for Neurodegeneration

Overview

P2X7 Receptor Antagonists for Neurodegeneration

Overview

P2X7 Receptor Activation and Neuroinflammation Pathway

P2X7 Receptor Biology

Structure and Function

Cellular Distribution

Mechanism of Action in Neurodegeneration

ATP as a Damage Signal

NLRP3 Inflammasome Activation

Microglial Polarization

Preclinical Evidence

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Other Neurodegenerative Conditions

Clinical Development

JNJ-47965567 (Johnson & Johnson)

AZD106 (AstraZeneca)

CE-224535 (Pfizer)

Other Clinical Candidates

Safety Profile

Adverse Events

Key Safety Considerations

Comparison to Other Anti-inflammatory Approaches

Cross-Links and Related Pages

Disease Pages

Mechanism Pages

Related Treatment Pages

Gene/Protein Pages

Research Challenges and Future Directions

Remaining Questions

Emerging Strategies

See Also

External Links

References

Related Hypotheses

💬 Discussion